louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT05659342: Comparison of ELDOA and Mechanical Traction Technique on Pain and Disability in Patients With Lumbar Disc Herniation
Official title: Comparison of ELDOA and Mechanical Traction Technique on Pain and Disability in Patients With Lumbar Disc Herniation
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Lumbar Disc Herniation
Lead sponsor: Riphah International University
Sponsor class: OTHER
First posted: 2022-12-21
Enrollment: 62
Sex: ALL
Minimum age (years): 20
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: To compare the effect of ELDOA and Mechanical traction technique on pain in patients with lumbar disc herniation.

To compare the effect of ELDOA and Mechanical traction technique on disability in patients with lumbar disc herniation.


Eligibility criteria: Inclusion Criteria:

* Age: 20-65 years
* Both gender Male \& Female
* Patients having Lumbar radiculopathy diagnosed with lumbar disc herniation.

Exclusion Criteria:

* Patients presented with motor deficit,
* Qauda equina syndrome,
* lumbar fracture
* spinal stenosis,
* osteophyte formation
* facet joint pathology
* spondylolisthesis.
* malignancy,
* degenerative disorders
* recent back surgery and patient whom surgery for lumbar disc herniation/prolapse intervertebral disc already advised by neurosurgeon

Primary outcomes:
measure: lumbar ROM by inclinometer.
timeFrame: 4 weeks
measure: pain on Numeric pain rating scale
timeFrame: 4 Weeks
measure: Modified Oswestry low back pain disability questionnaire
timeFrame: 4th Week
Secondary outcomes:
Other outcomes:
Locations:
city: Peshawar
country: Pakistan
facility: Lady Reading Hospital - Medical Teaching Institution
state: KP
Study officials:
affiliation: Riphah International University
name: Asghar Khan, DCS-PT
role: STUDY_CHAIR
References:
Clinical trial NCT01589406: Quality of Life and Sexuality in Women With Gynaecological Cancer
Official title: Quality of Life and Sexuality in Women With Gynaecological Cancer
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Cancer
Keywords: Gynaecological Cancer
Quality of Life
Sexuality
Lead sponsor: Rambam Health Care Campus
Sponsor class: OTHER
First posted: 2012-05-02
Enrollment: 100
Sex: FEMALE
Minimum age (years): 18
Maximum age (years): 70
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: women with Gynaecological cancer

Brief summary: Patients with premalignant (CIN3) and malignant cervical cancer will asked to complete questionnaires regarding intimacy (ENRICH) and life adaptation (PAIS) before treatment (surgery or radiotherapy) and after completion of treatment in order to estimate the influence of disease and treatment on quality of life indices.

Detailed description: no additional information. see above

Eligibility criteria: Inclusion Criteria:

* women with Gynaecological cancer intended to undergo chemotherapy or surgery

Primary outcomes:
measure: Quality of life
timeFrame: 2 years
Secondary outcomes:
Other outcomes:
Locations:
city: Haifa
country: Israel
facility: Rambam Medical Center
Study officials:
affiliation: Rambam Health Care Campus
name: Amnon Amit, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT02296606: Interrater Reliability of Subjective Pupillary Assessments
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Interrater Reliability Among Pupillary Assessments
Lead sponsor: University of Texas Southwestern Medical Center
Sponsor class: OTHER
First posted: 2014-11-20
Enrollment: 127
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Patients eligible for the study are those that have been diagnosed some form of brain trauma where brain swelling has been identified and pupil dilation has been incorporated into standard of care (e.g., TBI, stroke).

Brief summary: Prospective, observational, non-randomized study of interrater reliability of pupillary assessments, comparing two clinical assessments to the Pupillometer.


Eligibility criteria: Inclusion Criteria:

* Patients are eligible for this study if they have been diagnosed with some form of brain trauma (e.g., stroke, traumatic brain injury, aneurysm)

Exclusion Criteria:

* Prisoners
* Under 18 years of age

Primary outcomes:
measure: 1. Explore the Interrater Reliability of Pupillary Assessments When Conducted in the Natural Setting by a Diverse Group of Practitioners
timeFrame: 9 months of pupillary assessments
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT03700606: Physiological Changes With High-Flow Nasal Cannula
Official title: Physiological Changes With High-Flow Nasal Cannula Compared to Nasal CPAP in Extremely Low Birth Weight Infants
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Respiratory Distress Syndrome in Premature Infant
Keywords: high flow nasal cannula
nasal cpap
Lead sponsor: Sharp HealthCare
Sponsor class: OTHER
First posted: 2018-10-09
Enrollment: 80
Sex: ALL
Minimum age (years): 23
Maximum age (years): 29
Standard ages: CHILD
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: SUPPORTIVE_CARE

Brief summary: To measure changes in physiologic parameters in extremely low birthweight (ELBW) infants on high-flow nasal cannula compared to nasal continuous positive airway pressure (nCPAP).

Detailed description: After informed consent is obtained, eligible infants who are stable on nCPAP therapy of 5-7 cm H20 achieved with a ventilator, an underwater "bubble" system, or a variable-flow device will be enrolled.

All subjects will have physiologic data and electrical impedance tomography collected at:

1. Baseline nCPAP for 15 minutes
2. Upon transition to high flow nasal cannula at 8 LPM for 6 hours. Data collection is obtained after infant is calm for 15 minutes at the beginning and end of this 6 hour period
3. Then upon return to baseline NCPAP for a final 15 minutes of data collection.

Eligibility criteria: Inclusion Criteria:

* 23 to 28+6 weeks gestational age at birth
* Corrected gestational age less than or equal to 30 weeks
* Over 72 hours of life
* Stable on Nasal CPAP of 5-7cm H20
* Hemodynamically stable
* Tolerating routine handling
* Nares size appropriate for Fisher \& Paykel Optiflow Jr 2 HFNC size XS or small
* Successfully extubated for 12 hours after administration of surfactant
* Caffeine Citrate at a maintenance dose of 5 to 10 mg /kg
* Transcutaneous monitoring in place
* Stable blood gas (pH\>/= 7.25 and PaCO2 \<60 mmHg torr)

Exclusion Criteria:

* Prior pneumothorax or evidence of pulmonary interstitial emphysema.
* Prior or current pulmonary hemorrhage
* Congenital airway malformations
* Major cardiopulmonary malformations
* Congenital Diaphragmatic hernia or untreated bowel obstruction
* Poor respiratory drive unresponsive to CPAP therapy
* Requirement of a nCPAP of \>8 cmH20 or FiO2 \> 0.3 to maintain oxygen saturations between 90-95 percent.
* Receiving positive pressure breaths or SIPAP on prongs
* Conflicting clinical trial
* Clinically unstable per physician discretion

Primary outcomes:
measure: % Unventilated Lung
timeFrame: Through study completion, an average of 30 days
Secondary outcomes:
measure: Geometric Center of Ventilation (CoV)
timeFrame: Through study completion, an average of 30 days
measure: End-expiratory lung volume
timeFrame: Through study completion, an average of 30 days
Other outcomes:
Locations:
city: San Diego
country: United States
facility: Sharp Mary Birch Hospital for Women & Newborns
state: California
Study officials:
affiliation: Sharp HealthCare
name: Anup Katheria, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT06763406: The Effects of Schroth Based Exercise Therapy in Adolescents with Pectus Excavatum
Official title: The Effects of Schroth Based Exercise Therapy in Adolescents with Pectus Excavatum
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Pectus Excavatum
Pectus Excavatum Deformity
Funnel Chest
Chest Deformities
Keywords: Funnel chest
Pectus excavatum
Exercise
Exercise therapy
Vacuum
Tissue expansion devices
Lead sponsor: Hacettepe University
Sponsor class: OTHER
First posted: 2025-01-08
Enrollment: 35
Sex: ALL
Minimum age (years): 10
Maximum age (years): 18
Standard ages: CHILD
ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Research on exercise methods for pectus excavatum (PE) is limited, highlighting the need for further studies. This study investigated the effects of Schroth-based exercise therapy combined with vacuum treatment in 35 adolescents with PE, divided into a vacuum + exercise group (n=19) and a vacuum-only group (n=16). Outcomes included deformity severity, sagittal posture, thoracic cage and spinal mobility, muscle endurance, and quality of life. The combination therapy significantly improved sagittal spinal posture (craniovertebral, thoracic, thoracolumbar, lumbar angles) and deformity-specific quality of life (Nuss Questionnaire scores) compared to vacuum-only treatment.


Eligibility criteria: Inclusion Criteria:

* having pectus excavatum
* being 10-18 years
* having Haller index more than 2.5

Exclusion Criteria:

* Individuals with pectus excavatum associated with a syndrome Individuals with mixed deformity
* Individuals who have previously received any conservative treatment or surgery for chest deformity or spinal issues
* Individuals with neuromuscular, rheumatic, or chronic systemic diseases

Primary outcomes:
measure: Primary Outcome Measure 1: Deformity Severity
timeFrame: 12 weeks
measure: Primary Outcome Measure 2: Sagittal Spinal Posture
timeFrame: 12 weeks
measure: Primary Outcome Measure 3: Disease-Specific QoL
timeFrame: 12 weeks
measure: Primary Outcome Measure 4: General QoL
timeFrame: 12 weeks
Secondary outcomes:
measure: Secondary Outcome Measure 1: Thoracic Cage Mobility
timeFrame: 12 weeks
measure: Secondary Outcome Measure 2: Spinal Mobility
timeFrame: 12 weeks
measure: Secondary Outcome Measure 3: Lumbar Mobility
timeFrame: 12 weeks
measure: Secondary Outcome Measure 4: Muscle Endurance (Sit-Ups)
timeFrame: 12 weeks
measure: Secondary Outcome Measure 5: Muscle Endurance (Lateral Bridge)
timeFrame: 12 weeks
Other outcomes:
Locations:
city: Ankara
country: Turkey
facility: Hacettepe Uuniversity
state: Altındağ
Study officials:
References:
Clinical trial NCT02205606: Efficacy/Safety of HCP1306 Tablet Versus HGP0816 Tablet in Patients With Primary Hypercholesterolemia
Official title: A Randomized, Double-Blind, Multicenter, Phase 3 Study to Evaluate Efficacy and Safety of HCP1306 Tablet in Patients With Primary Hypercholesterolemia
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE3
Conditions: Primary Hypercholesterolemia
Lead sponsor: Hanmi Pharmaceutical Company Limited
Sponsor class: INDUSTRY
First posted: 2014-07-31
Enrollment: 412
Sex: ALL
Minimum age (years): 19
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to evaluate efficacy and safety of HCP1306 in patients with primary hypercholesterolemia.


Eligibility criteria: Inclusion Criteria:

* Aged over 19 years
* Signed informed consent
* At visit 1, LDL-C ≤ 250mg/dL and Triglyceride \< 400 mg/dL
* After 4 weeks more TLC, At visit2, LDL-C ≤ 250mg/dL, Triglyceride \< 400 mg/dL and satisfied criteria according to Risk of cardiovascular disease

Exclusion Criteria:

* Current or past history of hypersensitivity to HMG-CoA reductase inhibitors and component of Ezetimibe
* Has an active liver disease and severe liver disorder (continous elevation of AST, ALT level or exceeds more than 3 times of normal upper limit)
* Has a severe renal failure and kidney injury (Creatinine level exceeds more than 2 times of normal upper limit)
* CK level exceeds more than 5 times of normal upper limit
* Uncontrolled hypertension patient (SBP≥ 180 mmHg or DBP ≥ 110 mmHg)
* Uncontrolled diabetes mellitus patient (HbA1c ≥ 9%)
* Uncontrolled malfunctional thyroidism (or at pre-visit 2, TSH level exceeds more than 1.5 times of normal upper limit)

Primary outcomes:
measure: Percent change from baseline to 8 week in LDL-Cholesterol
timeFrame: baseline and 8 week
Secondary outcomes:
measure: Percent change from baseline to 4 week in LDL-Cholesterol
timeFrame: baseline and 4 week
measure: Percentage of patients reaching treatment goals according to NCEP ATP III Guideline
timeFrame: week 4, week 8
measure: Percent change from baseline to 4 week and 8 week in TC
timeFrame: week 4, week 8
measure: Percent change from baseline to 4 week and 8 week in HDL-C
timeFrame: week 4, week 8
measure: Percent change from baseline to 4 week and 8 week in TG
timeFrame: week 4, week 8
Other outcomes:
Locations:
city: Seoul
country: Korea, Republic of
facility: 19 institutions including Seoul National University Hospital
Study officials:
affiliation: Seoul National University Hospital
name: Hyo-soo Kim, MD, Ph.D.
role: PRINCIPAL_INVESTIGATOR
References:
citation: Rhee MY, Kim KJ, Kim SH, Yoon YW, Rha SW, Hong SJ, Kwak CH, Kim W, Nam CW, Park TH, Hong TJ, Park S, Ahn Y, Lee N, Jeon HK, Jeon DW, Han KR, Moon KW, Chae IH, Kim HY, Kim HS. Ezetimibe and Rosuvastatin Combination Treatment Can Reduce the Dose of Rosuvastatin Without Compromising Its Lipid-lowering Efficacy. Clin Ther. 2019 Dec;41(12):2571-2592. doi: 10.1016/j.clinthera.2019.10.010. Epub 2019 Nov 11.
Clinical trial NCT01330706: Efficacy of Intraoperative Surgical Scrubbing in Reducing Bacterial Load After Nail Removal Surgery
Official title: Efficacy of Intraoperative Surgical Scrubbing in Reducing Bacterial Load After Nail Removal Surgery
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: Skin Diseases
Nail Diseases
Nails, Ingrown
Keywords: Skin Diseases [C17.800]
Nail Diseases [C17.800.529]
Nails, Ingrown [C17.800.529.406]
Lead sponsor: Universidad Complutense de Madrid
Sponsor class: OTHER
First posted: 2011-04-07
Enrollment: 50
Sex: ALL
Minimum age (years): 18
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: The investigators conducted a controlled, prospective randomized study to examine the antiseptic efficacy of intraoperative irrigation methods during nail avulsion surgery.

Detailed description: The investigators conducted a controlled, prospective randomized study to examine the antiseptic efficacy of intraoperative scrubbing methods during nail avulsion surgery. The investigators compared intraoperative antiseptic scrubbing using 0.9% saline solution and 0.1% polihexanide. Swab samples were taken from each patient at 5 distinct stages throughout the surgical procedure, and bacterial culture analysis was performed (positive culture rate, total inocula count, reduction of bacterial load, and identification of specific microorganisms).

Eligibility criteria: Inclusion Criteria:

* Older than 18
* Onychocryptosis

Exclusion Criteria:

* infection
* a history of tinea pedis
* onychomycosis
* paronychia
* nail trauma or subungual hematoma
* nail deformities and disorders
* peripheral vascular disease or diabetes
* cardiac disease
* a history of rheumatic fever
* recent antibiotic use or current antimicrobial therapy
* a history of steroid use and
* recent nail polish use

Primary outcomes:
measure: bacterial count (CFU/cm2)
timeFrame: Participants will be followed until the surgery to heal completely,an expected average of 7 weeks
Secondary outcomes:
Other outcomes:
Locations:
city: Madrid
country: Spain
facility: Universidad Complutense de Madrid
Study officials:
affiliation: Universidad Complutense de Madrid
name: Ricado Becerro de Bengoa Vallejo, PhD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Becerro de Bengoa Vallejo R, Losa Iglesias ME, Cervera LA, Fernandez DS, Prieto JP. Efficacy of intraoperative surgical irrigation with polihexanide and nitrofurazone in reducing bacterial load after nail removal surgery. J Am Acad Dermatol. 2011 Feb;64(2):328-35. doi: 10.1016/j.jaad.2010.01.011. Epub 2010 Nov 26.
Clinical trial NCT04110106: Correlation Between Quality of Life and Severity of Parkinson's Disease
Official title: Correlation Between Quality of Life and Severity of Parkinson's Disease by Assessing an Optimal Cut-off Point on the Parkinson's Disease Questionnaire (PDQ-39) as Related to the Hoehn & Yahr (H&Y) Scale
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Parkinson Disease
Quality of Life
Lead sponsor: R.O.M.A. - Rehabilitation & Outcome Measures Assessment
Sponsor class: OTHER
First posted: 2019-10-01
Enrollment: 513
Sex: ALL
Minimum age (years): 50
Maximum age (years): 90
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: CROSS_SECTIONAL
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Fivehundred thirteen individuals with Parkinson's Disease (PD) were recruited, all of whom agreed to participate and were thus included in the study. From the general analysis resulted that the greatest number of participants were stage II, according to Hoehn \& Yahr (H\&Y), followed by stage III, stage I, and finally stage IV. Participants between the age of 50 and 69 were mainly stage I or II, while participants aged 70 to 89 had a greater severity of PD (stage II and III). Most women were in H\&Y stage II and III, while most men were mainly in stage II, followed by stage I and III, with a very similar number of participants. A common result for all analyses was the presence of a very low number of participants with stage IV.

Brief summary: This study aim to evaluate the correlation between Quality of Life (QoL) and severity of Parkinson's Disease (PD) by assessing the presence of an optimal cut-off point on the Parkinson's disease questionnaire (PDQ-39) as related to the Hoehn \& Yahr (H\&Y) scale in a cohort of Italian adults with PD.

A multicenter, cross-sectional study was performed in central and northern Italy. This study was conducted on a cohort of consecutive individuals at three neurologic outpatient clinics. All participants were evaluated with the PDQ-39, and the severity of PD was recorded according to the H\&Y scale by a neurologist. Receiver operating characteristic (ROC) curves and coordinates of the curve, which were visually inspected, were used to find cut-off points with optimal sensitivity and specificity. These were in turn used to determine the optimal PDQ-39 cut-off score for identifying disease severity according to H\&Y stages.


Eligibility criteria: Inclusion Criteria:

* age \> 50 but \< 90 years,
* H\&Y stages I, II, III, and IV,
* a mini-mental state examination \> 22 points,
* a minimum level of five years of education.

Exclusion Criteria:

* Individuals with emotional or psychiatric problems (as determined by clinical screening)

Primary outcomes:
measure: Hoehn & Yahr (H&Y)
timeFrame: at admission to the neurologic outpatient clinics
measure: Parkinson's Disease questionnaire (PDQ-39)
timeFrame: at admission to the neurologic outpatient clinics
Secondary outcomes:
Other outcomes:
Locations:
city: Roma
country: Italy
facility: Department of Human Neurosciences, Sapienza University of Rome
state: RM
Study officials:
References:
Clinical trial NCT05662306: C-Cog in Early Course Schizophrenia Study
Official title: Comprehensive Treatment of Early Course Schizophrenia: A Nonrandomized Study of Long Acting Injectable Antipsychotic Medication Combined With Cognitive and Functional Skills Training
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: PHASE4
Conditions: Schizophrenia
Keywords: Relapse
Remission
Recovery
Lead sponsor: University of Miami
Sponsor class: OTHER
Collaborators: name: Alkermes, Inc.
First posted: 2022-12-22
Enrollment: 60
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to examine the role of clinical stability in functional recovery. in first episode schizophrenia.


Eligibility criteria: Inclusion Criteria:

1. Adults
2. Diagnosis of schizophrenia
3. Current Hospitalization or outpatient relapse
4. Fewer than four previous admissions
5. Willing to accept long-acting injectable treatment and participate in rehabilitation

Exclusion Criteria:

1. Primary diagnosis other than schizophrenia
2. Prior Long Acting Injectable treatment
3. Current Suicide Risk
4. Hypersensitivity to Aripiprazole
5. Pregnancy
6. Positive illicit drug screen other than cannabis (rescreening allowed in 4 weeks for drug positive cases)
7. Unable to give personal informed consent
8. History of treatment resistance as evidenced by clozapine treatment
9. Unable to stop treatment with medications that are strong Cytochrome (CYP) 2D6 or CYP 3A4 inhibitors and or strong CYP3A4 inducers (2.3, 7.1) for at 14 days prior to initiation.

Primary outcomes:
measure: The percentage of participants who develop sustained remission of symptoms of schizophrenia as measured as having a score of 3 or less on all 6 critical items from the Positive and Negative Syndrome Scale (PANSS)
timeFrame: 6 months
Secondary outcomes:
Other outcomes:
Locations:
city: Miami
country: United States
facility: Jackson Memorial Hospital
state: Florida
Study officials:
affiliation: University of Miami Miller School
name: Dante Durand, MD
role: PRINCIPAL_INVESTIGATOR
References: